达雷妥尤单抗、卡非佐米、来那度胺和地塞米松联合串联移植治疗高危新诊断骨髓瘤
这项2期研究评估了D-KRd诱导巩固联合串联自体干细胞移植在高危适合移植的新诊断多发性骨髓瘤患者中的可行性,50例患者入组,中位年龄57岁,主要终点达到,36例完成第二次移植,总缓解率100%,完全缓解率81%,微小残留病阴性率94%,中位随访33个月,30个月无进展生存率80%,总生存率91%。
要点
- D-KRd联合串联移植在高危适合移植新诊断骨髓瘤中可行,36例完成第二次移植。
- 完成第二次移植患者总缓解率100%,完全缓解率81%,维持治疗前MRD阴性率94%。
- 中位随访33个月,30个月PFS率80%,OS率91%。
核心结论
- D-KRd联合串联移植在高危适合移植的新诊断多发性骨髓瘤患者中可行,并带来高缓解率和无进展生存。
研究设计与样本
- 法国骨髓瘤协作组(Intergroupe Francophone du Myelome)开展的2期研究2018-04,纳入50例既往未治疗的高危适合移植新诊断多发性骨髓瘤患者,中位年龄57岁。
- 高危细胞遗传学定义为存在del(17p)、t(4;14)和/或t(14;16)。
- 治疗包括D-KRd诱导、自体干细胞移植、D-KRd巩固、第二次自体干细胞移植和达雷妥尤单抗-来那度胺维持。
- 主要终点为可行性。
主要发现
- del(17p)、t(4;14)和t(14;16)分别见于40%、52%和20%的患者。
- 数据截止时研究达到主要终点,36例患者完成第二次移植。
- 20例患者终止研究,原因包括干细胞采集失败(n=8)、疾病进展(n=7)、不良事件(n=4)和撤回知情同意(n=1)。
- D-KRd诱导/巩固相关3-4级不良事件(>5%患者)包括中性粒细胞减少(39%)、贫血(12%)、血小板减少(7%)和感染(6%)。
- 完成第二次移植患者的总缓解率为100%,包括81%完全缓解;维持治疗前微小残留病(10-6)阴性率为94%。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
High-risk (HR) cytogenetics are associated with poor outcomes in newly diagnosed multiple myeloma (NDMM), and dedicated studies should address this difficult-to-treat population. The phase 2 study 2018-04 from the Intergroupe Francophone du Myelome evaluated feasibility of an intensive strategy with quadruplet induction and consolidation plus tandem transplant in HR transplant-eligible (TE) NDMM. HR cytogenetics were defined by presence of del(17p), t(4;14), and/or t(14;16). Treatment consisted of daratumumab-carfilzomib-lenalidomide-dexamethasone (D-KRd) induction, autologous stem cell transplantation (ASCT), D-KRd consolidation, second ASCT, and daratumumab-lenalidomide maintenance. The primary end point was feasibility. Fifty patients with previously untreated NDMM were included. Median age was 57. Del(17p), t(4;14), and t(14;16) were found in 40%, 52%, and 20% of patients, respectively. At data cutoff, the study met the primary end point with 36 patients completing second transplant. Twenty patients discontinued the study due to stem cell collection failure (n = 8), disease progression (n = 7), adverse event (n = 4), or consent withdrawal (n = 1). Grade 3 to 4 D-KRd induction/consolidation-related adverse events (>5% of patients) were neutropenia (39%), anemia (12%), thrombocytopenia (7%), and infection (6%). The overall response rate was 100% for patients completing second transplant, including 81% complete response. Premaintenance minimal residual disease (MRD) negativity rate (10-6) was 94%. After a median follow-up of 33 months, the 30-month progression-free survival (PFS) and overall survival were 80% and 91%, respectively. In conclusion, D-KRd with tandem transplant is feasible in patients with HR TE-NDMM and resulted in high response rates and PFS. This trial was registered at www.clinicaltrials.gov as #NCT03606577.
引用
- Touzeau C, Perrot A, Hulin C, et al. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma. Blood. 2024. PMID: 38394666. doi:10.1182/blood.2023023597
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。